Nano Anti-Cancer Drugs: Pros and Cons and Future Perspectives
Keywords: Deoxyribo nucleic acid; Inter Leukin-12; Inter Leukin-6; Interferon-; Multi drug resistance; Nano anti-cancer drugs; Poly ethylene glycol; Red blood corpuscles; Small interfering ribo nucleic acids; Tumor necrosis factor; White blood corpuscles; chemotherapy; dendrimers; dendritic cells; fibrosis; future perspectives; gadolinium; immune system; micelles; micro-capsules; multidrug resistance; neutropenia; paclitaxel; pros and cons; serum transaminase levels; special features; synergistic efficacy; thrombocytopenia; toxicities; tumor
Document Type: Research Article
Publication date: 01 February 2011
- Current Cancer Drug Targets aims to cover all the latest and outstanding developments on the medicinal chemistry, pharmacology, molecular biology, genomics and biochemistry of contemporary molecular drug targets involved in cancer, e.g. disease specific proteins, receptors, enzymes, genes.
Each issue of the journal contains a series of timely in-depth reviews written by leaders in the field covering a range of current topics on drug targets involved in cancer.
As the discovery, identification, characterization and validation of novel human drug targets for anti-cancer drug discovery continues to grow; this journal has become essential reading for all pharmaceutical scientists involved in drug discovery and development.